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Abstract 
The immense corpus of biomedical literature existing today poses challenges in information search and integration. Many 
links  between  pieces  of  knowledge  occur  or  are  significant o n l y  u n d e r  c e r t a i n  c o n t e x t s —rather  than  under  the  entire 
corpus. This study proposes using networks of ontology concepts, linked based on their co-occurrences in annotations of 
abstracts of biomedical literature and descriptions of experiments, to draw conclusions based on context-specific queries and 
to better integrate existing knowledge. In particular, a Bayesian network framework is constructed to allow for the linking of 
related terms from two biomedical ontologies under the queried context concept. Edges in such a Bayesian network allow 
associations between biomedical concepts to be quantified and inference to be made about the existence of some concepts 
given prior information about others. This approach could potentially be a powerful inferential tool for context-specific 
queries, applicable to ontologies in other fields as well. 
1  Introduction and Objective 
The millions of published works of biomedical literature cover an enormous array of knowledge. Over 21 million articles are 
indexed  in  PubMed  alone,  and  around  700,000  new  articles  are  added  yearly
1.  Additionally,  data  from  millions  of 
experiments are archived in diverse databases. The large size of today’s body of biomedical knowledge and swiftness with 
which new information is being added present challenges in organization and navigation. The rise of such a large amount of 
information in recent years is changing the nature of biological knowledge from a descriptive practice to a more data-driven 
one, and finding specific information through manual search is growing increasingly difficult. 
Biomedical ontologies can potentially be used to address these challenges. Tremendous efforts have been made to create 
diverse ontologies that together include all biomedical concepts. The National Center of Biomedical Ontology (NCBO) 
BioPortal
2,3 provides over 250 such ontologies wi t h ove r  5 mi l l i on c onc e pt s
6 t o r e s e a r c he r s . Moreover, researchers use 
ontology  terms  to  annotate  experimental  data  and  works  of  literature.  Hence,  an  automated,  efficient  framework  that 
navigates and integrates the information embedded in these ontological links would be a powerful research tool that utilizes 
an immense range of biomedical knowledge. However, ontologies are usually developed in a silo, and the separateness of 
ontologies  has s o  f a r  h i n d e r e d  t h e  p r a c t i c a l  a p p l i c a t i o n  o f  o n t o l o g i c a l  o r g a n i z a t i o n .  H e n c e ,  a  c r u c i a l  q u e s t i o n  r e m a i n s  
unanswered: is it possible to automatically and efficiently use biomedical ontologies to infer new knowledge?  
This work presents such an automated framework that integrates biomedical ontologies and infers knowledge from abstracts 
of literature and descriptions of experimental data in response to a user-defined query. In particular, this framework infers 
information particular to a given context, or situation. Context-specificity is useful because researchers often have questions 
relevant to specific situations, and the same biological concepts may be linked in some contexts but not in others. For 
example, two traits might not generally be observed together, but in the context of a specific genetic condition, they may 
coexist frequently. The proposed framework identifies these types of linkages. 
2  Mapping Ontologies: An Overview 
A logical first step is to integrate the disparate biomedical ontologies. We seek a reliable framework for mapping ontological 
relationships  that  (1)  considers  diverse  types  of  relationships  between  terms,  (2)  accounts  for  uncertainty i n  o n t o l o g y  
integration, (3) is scalable to the size of biomedical ontologies, and (4) is able to be tailored to specific contexts. So far, no 
such framework has been developed.   
The Unified Medical Language System (UMLS)
4 has integrated over 2 million names for approximately 900,000 biological 
concepts. However, mappings of UMLS concepts were manually curated, so there remain inconsistencies and errors in the 
mappings, and it is difficult for mappings to keep pace with the rate at which knowledge is expanding
5. Many non-manual 
methodologies exist for ontological integration, including semi-automatic methods such as PROMPT
7 and GLUE
8, and 
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automatic  methods s u c h  a s  I F -MAP
9,  ANCHOR-PROMPT
10, a n d  M A F R A
11.  In C h u a  e t  a l .
12, m o r e  t h a n  3 0  ontology 
mapping methods are surveyed and categorized into 7 categories. However, almost all proposed methods are not publicly 
available or are not scalable to the size of biomedical ontologies
13.  
Two recent methods, Association Rule Ontology Matching Approach (AROMA)
14 and Lexical OWL Ontology Matcher 
(LOOM)
13, are publicly available and easily scalable. These two methods differ significantly. LOOM is used for discovering 
equivalence correspondences between concepts, is based on lexical matching, and does not require text corpora to work. In 
contrast, AROMA is used for inferring subsumption relationships between concepts, is based on a statistical measure known 
as implication intensity, and requires additional text corpora. Though these methods are steps forward, they do not consider 
the inevitable uncertainty of ontology mapping.   
Some ontology-mapping studies do consider uncertainty by incorporating probabilistic uncertainty into their description logic 
by using Bayesian networks
15-19. For example, a framework called OMEN
16 creates Bayesian networks of ontologies by 
drawing initial probabilities from a priori knowledge and then using a set of meta-rules to determine conditional probabilities 
between nodes. The conditional probabilities represent influences induced by nodes on their children. Two other algorithms, 
MSBN
17 and AEBN
18, create pairwise correspondences between semantically identical concepts and propagate information 
through  these  correspondences  between  two  ontology-specific  Bayesian  networks.  The  algorithm  BayesOWL
15 u s e s  a  
process similar to those of MSBN and AEBN but is more comprehensive: it links similar concepts as well as identical 
concepts by defining the similarity of concepts probabilistically by their joint distribution. More methods for probabilistic 
modeling of uncertainty in linking ontologies can be found in Lukasiewicz
20 
3  Context-Specific Ontology Mapping and Probabilistic Inference: A Novel Technique 
The method presented in this paper is distinct from the aforementioned ontology-mapping methods in its use of a context-
sensitive algorithm. In prior work, a context-specific mapping algorithm based on the Bayes factor
21 was developed. This 
study  adapts  and  applies t h a t  m a p p i n g  m e t h o d  to  construct t h e  b a c k b o n e s o f  c o n t e x t -centered  Bayesian  networks f o r  
inference about biomedical relationships. This context-specific mapping approach has three main advantages: (1) mappings 
created are specific to the question under investigation, so unrelated concepts are pruned; (2) inference is less prone to noise 
generated from considering many unrelated concepts and can be more accurate; and (3) pruning many irrelevant concepts 
allows the inference algorithm to be scaled to the large size of most biomedical ontologies.  
Once the Bayesian backbone is constructed, probabilistic inference on the framework accounts for conditional uncertainties in 
biological connections in the given context and gives more nuanced conclusions. The prior study
21 focused primarily on 
gathering the literature base and developing the Bayes factor to conduct univariate linkage analysis between terms; here, the 
Bayes factor is used as a tool to consider multivariate relationships and in a high-dimensional Bayesian network, leading to 
more nuanced and meaningful results. 
4  Materials and Methods 
The proposed framework constructs and analyzes networks based on knowledge embedded in ontological annotations of 
descriptions of experimental data and abstracts of published literature. After obtaining an annotated knowledge database, the 
framework comprises three main stages: (1) defining the query, (2) constructing a Bayesian graph based on that query, and 
(3) using that graph to perform probabilistic inference.  
4.1 The Annotated Knowledge Base 
Table 1: Sources of records in the knowledge base. Records were compiled in 2009. For all sources except PubMed, every 
existing record was included in the knowledge base. For efficiency, 100,000 PubMed records were randomly selected from 
the 16,000,000 existing at the time. A B-tree index was created on the records for searching. 
Source Database 
Stu 
Records    Source Database 
Stu 
Records 
Adverse Event Reporting System
14  774,606    Drug Bank
20  4774 
Array Express
15  9281    Database of Phenotypes and Genotypes
21  75,828 
BioSiteMaps
16  1013    Gene Expression Omnibus
22  15,968 
caNanoLab
17  444    Stanford Microarray Database
23  16,148 
Conserved Domain Databases
18  34,735    Published articles in PubMed
24  100,000 
Clinical Trials Database
19  75,828    Drug Bank
20  4774 
We prepared an indexed B-tree for searching the knowledge base that comprised annotated records from eleven corpora 
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available from NCBO Bioportal in 2009 (Table 1). Then, 220 ontologies were obtained from the NCBO BioPortal; for 
caching sufficient statistics when searching through the literature, the dictionary of all available ontology concepts (4,153,358 
terms) was obtained. More details on preparation of this B-tree and the ontology data are provided in Kshitij et al.
21 
4.2 Queries 
In this work, a query consists of a concept of interest (the context under which linkages are identified) and two ontologies 
(containing the terms between which linkages are drawn). One ontology is designated the source ontology; the other is 
designated the destination ontology. Users define elements of their queries based on their applications. For example, a 
researcher interested in obesity-related phenotypes and genes might choose “obesity” for the context and Human Phenotype 
Ontology and Gene Ontology for the two ontologies.  
4.3 Constructing the Network   
Determining the Network Structure 
Based on the query, a tree-augmented naïve (TAN) Bayesian network is constructed, where each node is a random variable 
that represents the state a specific concept takes in an annotation (either “exists” or “does not exist”). Nodes corresponding to 
concepts from the source ontology are the parents of nodes corresponding to concepts from the destination ontology. The root 
node corresponds to the context concept and is a parent of all nodes in the network. The TAN structure is adopted because its 
requirement that the root node is a parent of every other node parallels the way the context term is present when every 
ontological connection is identified. The structure is appropriate for context-specific inference. 
The time complexity of learning a TAN structure from data using a maximally weighted spanning tree algorithm
25 is O(n
2N), 
where n is the number of features (the number of concepts in both the source and the destination ontologies), and N is the 
number of samples
26.  In this study, the data is a large collection of literature annotated by ontologies. However, the large size 
of biomedical ontologies renders the use of the original TAN learning structure
25 infeasible. Hence, this framework uses a 
Bayes factor
23 (BF) to identify linkages between any source concept S and any destination concept D under a given context 
concept C
7. The higher the Bayes factor, the larger the magnitude of association between two random variables. Therefore, 
we prune many weak linkages between S and D under C and map only S and D concepts that share a mutual BF greater than 
a threshold value.  
 
 
 
 
 
 
Figure 1: The context-specific ontology-mapping process. This diagram shows the source term “polycystic ovaries” being 
mapped to the destination term “chemoorganotrophy” under the context “obesity.” Bold green arrows represent associations 
between concepts. In general, a source term and a destination term are mapped if and only if they are significantly associated 
with one another in annotations containing the context concept. 
In order to calculate the BF between any S and D considering the context C, we first create a 2-by-2 contingency table. Each 
element of this table is determined from the frequencies of co-occurrences of S and D in literature that contain C. Let n  be the 
number of documents, its subscript (S, D, or C) be the type of concept being counted, and the superscript (+ or –) be the state 
of the concept, where a plus sign (+) signifies “exists” and a minus sign (–) signifies “does not exist.” The contingency table 
contains  n
++ ,  n
+− ,  n
−+ , and n
−− . Counts are obtained through full-text searches of the knowledge database (Table 1) and 
are used to calculate BF using the procedure described in Albert
27. However, BF is not calculated for every pair of S and D: 
the hierarchical structure of ontologies allows a more efficient depth-first branch-and-bound algorithm
28 to be used to traverse 
the two ontologies. 
After all significantly co-occurring pairs of S and D under the context C are linked, in accordance to the TAN structure, every 
concept in the network is linked to the context concept as well. The same destination concept may appear several times, each 
time linked to a different source concept, because of the TAN requirement that nodes have no more than one non-root parent. 
The different instances of the same destination concept are not considered as one node because keeping them separate 
drastically facilitates probabilistic inference. 
 
polycystic  
ovaries
source: 
HUMAN  DISEASE context: 
OBESITY
destination: 
GENE  ONTOLOGY
chemo- 
organotrophy
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Associating Edges with Conditional Probabilities 
The network must next be associated with probabilities. For each concept in the net, a table containing the conditional 
probabilities that each of its states (“exists” or “does not exist”) is true is determined for all combinations of states its parent 
nodes can take. The conditional probability values are derived from the counts of different combinations of the states of the 
concept in question and its parents in annotations. For example,  P(C
+)= n
C
+ (n
C
+ +n
C
−) is one context probability value, 
P(S
+ C
+)= n
S
+C
+ (n
S
+C
+ +n
S
−C
+) is one source probability value, and  P(D
+ S
+C
+)= n
D
+S
+C
+ (n
D
+S
+C
+ +n
D
−S
+C
+)  is one 
destination probability value. Queries are performed, and counts are collected in the same way as when calculating the Bayes 
factor to build the network structure. Based on transitive closure of concepts in ontologies, we used the same depth-first 
branch-and-bound procedure described in Kshitij et al.
21 to prune the ontologies and cache the statistics. This pruning makes 
the Bayesian network construction efficient enough and scalable to the size of biomedical ontologies.  
The final product is thus a three-tiered TAN Bayesian network with the context term at the root, source ontology terms as 
intermediates, and destination ontology terms as the leaves, related to one another by conditional probabilities based on the 
frequencies of their co-occurrence in annotations of literature and of experimental data. 
The power of these networks comes from Bayesian inference. Because nodes are linked by probabilities, given the prior 
probability distribution of the root nodes, predictions can be made about the states of any of the other nodes. In this study, 
Pearl’s message-passing algorithm in trees
25 is implemented so that state information about one or more nodes can propagate 
along the graph edges and influence the probabilities of the states of other nodes. For example, if certain biological concepts 
are known to be affected, expressed, or active, the nodes corresponding to those concepts are set to true (P(exists) = 1). The 
tree is then updated to reflect this new knowledge, and P(exists) values of all other nodes change accordingly. 
4.4  Probabilistic Inference on the Network 
Identifying Inter-Concept Linkages Using Belief Propagation 
The power of these networks lies in Bayesian inference. Because nodes are linked by probabilities, predictions can be made 
about the states of any of the other nodes given the prior probability distribution of the root nodes. Pearl’s message-passing 
algorithm
29 is implemented so that state information about one or more nodes can propagate along the graph edges and 
influence the probabilities of the states of other nodes. For example, if certain biological concepts are known to be affected, 
expressed, or active, the nodes corresponding to those concepts are set to true (P(exists) = 1). The tree is then updated to 
reflect this new knowledge, and P(exists) values of all other nodes change accordingly. 
One application of the constructed networks and the proposed inference algorithm is the identification of source or destination 
concepts in the network that are related to the context C. To measure the relatedness of a term T to the context, we associate it 
with a likelihood ratio L:   
                              L =
P(T exists C exists)
P(T exists C does not exist)
                                              (1) 
To calculate L, state of the context node is set to “exists,” and the states of all other nodes are left unknown. Beliefs are then 
propagated, and  P(T exists C exists) is found for each node. The context node is then set to “does not exist,” and the other 
nodes are still left with unknown states. Again, beliefs are propagated, and  P(T exists C does not exist) is found for each 
node. L is the ratio of those two probabilities. It measures how much more likely it is that T is true when C is true than when C 
is false, not simply how likely it is that the two terms coexist. Hence, a general term such as “disease/disorder” would not 
score a high L because there would be little difference in the probability that it exists whether or not the context is true. That is, 
the terms with the highest L are most likely to be related specifically to the context and are therefore terms of interest.  
A p-value can also be found for each T-C link. First, the Bayes factor that T and C are associated is determined again in the 
manner described in Section 4.2, except this time the contingency table contains n
T
+C
+ , n
T
+C
− , n
T
−C
+ , andn
T
−C
− . Using that 
BF, an upper bound for the p-value can be determined as follows
36, where p < 1/e:
 
 
−pln p <
1
BF⋅e
 
This study examines the terms with the highest L as the “most related” and then separately associates them with p-values for 
ease of understanding. This choice was made because L, which is based on probabilistic propagation over the network, 
considers all terms in a high-dimensional joint distribution, whereas using Bayes factor or p-value as the final mapping is 
essentially a univariate, deterministic linkage from source to context. Without using L, the benefits of considering intricate, 
multivariate biomedical relationships represented in the network would be lost. 
28   
Extending the Network: Gene Inference 
Inference using the Bayesian framework is not limited to identification of connections between ontological concepts. For 
example, the framework can be used to identify the genes most relevant to a queried context. To do so, networks are built 
with Gene Ontology (GO) as one of the two queried ontologies, and GO concepts in the network are linked with relevant 
genes based on gene set information from MSigDb
46. Because links between genes and GO concepts are deterministic, this 
additional gene level is not actually part of the probabilistic inference framework, and genes do not correspond to network 
nodes. Therefore, the inference procedure for finding genes relevant to a given context cannot rely on belief propagation. 
Instead, relatedness of genes to the context are determined based on network structure alone. For each gene, a one-sided 
Fisher’s exact test is used to determine whether there is a significant difference between the proportion of GO terms in the 
network (which are presumably related to the context) that are associated with that gene and the proportion of GO terms 
outside  the  network  (which  are  conversely  not  strongly  related  to  the  context)  that  are  associated  with  the  gene.  The 
Benjamini-Hochberg method was used to control for the false discovery rate from multiple hypotheses
47. 
5  Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: TAN Bayesian network constructed for context “obesity.” Yellow nodes represent GO (destination) terms; light 
blue nodes represent DOID (source) terms, and the orange node represents the context. Displayed are 4401 out of the 447374 
total edges in the network; the full network contains 240 unique nodes from DOID and 8218 unique nodes from GO. 
Magnified views of the circled subnets are provided in Fig. 3.  
In this work, we use the proposed learning network structure and inference procedures to identify diseases and genes related 
to specific pathologies of interest. The context concept is set to be the pathology, the source ontology is set to be Human 
Disease (DOID), and the destination ontology is set to be Gene Ontology (GO). Both ontologies are available through NCBO 
BioPortal
2,3.  That  way,  all  biomedical  relationships  represented  in  the  Bayesian  network  are  specific  to  the  context  or 
pathology of interest. Since, as explained in Section 4, inference is done over this context-specific network, all identified 
relationships are tailored for the context.  
Networks  were  constructed  and  analyzed  for  diverse  context  pathologies,  including  several  cancers,  substance  abuse 
disorders, obesity and heart disease, and HIV/AIDS. Similar patterns were observed in the results of all contexts; results from 
contexts “alcoholism” and “obesity” are discussed further in this paper. The network built using context “obesity” is shown in 
Figure 2. In the rest of Section 5, italicized body text represents terms or genes identified by the algorithm as associated with 
the context.  
 
  Fig. 3a
obesity
  Fig. 3b
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Figure 3: Magnified views of circled subnets in Fig. 2. Nodes are color-coded as in Fig. 2. a) This subnet is centered about 
the DOID (source) concept “congenital thyroglossal cyst,” a parent of numerous GO (destination) concepts. b) This subnet 
has the DOID (source) concept “congenital thyroglossal cyst.” True to the TAN structure, the context node “obesity” is a 
parent of all other nodes as well. 
5.1 Alcoholism 
 
 
 
 
 
 
 
 
 
 
Table 2. The ten Disease Ontology (source) terms identified as most strongly linked to the context “alcoholism.” 
The disease concepts with the strongest links to the context “alcoholism” using (1) as a measure of link strength are indeed 
closely biologically related to alcoholism (Table 2). Alcoholism is a substance-related disorder, is a form of addiction, and 
would be associ at ed wi t h alcohol-related disorders NOS. Alcohol consumption is known to interfere with the nervous 
system, leading to impaired perception, coordination, memory, and judgment, all possible components of organic mental 
disorder of unknown etiology
38,39. Psychotic disorders such as schizophrenia occur more frequently in alcoholics than in 
nonalcoholics
40,41, and alcohol consumption can lead to tauopathies, diseases involving aggregation of abnormal tau protein in 
the brain
42, such as Alzheimer’s dementia
43. Moreover, environmental factors such as socioeconomic status or education 
quality play major roles in the development of alcoholism, a disease of environmental origin or environmentally induced 
disease
44, and there exists a high comorbidity between drug abuse problems and alcoholism
45.  
The gene inference procedure (Section 4.4) identified many promising genes as significant. For example, a number of genes 
had already been found by other studies to be associated with the context of alcoholism, including PTGDS (P < 10
-15), the 
gene  with  the  lowest  p-value; MIF (P <  1 0
-13);  BRCA1 ( P < 1 0
-13);  IL4 ( P <  1 0
-7);  and  the  three  types  of  peroxisome 
Disease Term  L  BF  p-value  
Drug abuse  340.755  12.949  4.187 × 10
-4 
Alcohol-related disorder NOS  294.652  12.460  5.718 × 10
-3 
Substance-related disorder 
 
185.522  11.309  6.450 × 10
-3 
Disease of environmental origin  74.763  8.707  8.962 × 10
-3 
Environmentally induced disease  74.763  8.707  8.962 × 10
-3 
Addiction   68.806  10.934  6.726 × 10
-3 
Schizophrenia  24.199  5.157  1.768 × 10
-2 
Alzheimer’s dementia  16.957  3.400  3.121 × 10
-2 
Organic mental disorder of unknown etiology  6.543  6.341  1.345 × 10
-2 
Tauopathies  5.114  6.007  1.445 × 10
-2 
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proliferator-activated receptor genes (PPARs), PPARA (P < 10
-15), PPARD (P < 10
-15), and PPARG (P <  10
-5). PTGDS codes 
for prostaglandin D2 synthase, which is negatively correlated with alcohol intake
48. In liver tissues affected by alcoholic liver 
disease, serum levels of macrophage migration inhibitory factor, coded by MIF, are elevated
49, while alcohol inhibits IL4, 
which  controls  B-cell  proliferation  and  immunoglobulin  class  switching
50,51.  Alcohol  consumption  is  associated  with 
heightened incidence of breast cancer, and ethanol down-regulates BRCA1, the second most likely gene, of which mutations 
are closely linked to breast cancer
52,53. Both PPARA and PPARD are downregulated by ethanol, PPARD agonists alleviate 
alcohol-induced liver damage, and PPARG activation may suppress addictive drinking behaviors
54. Other significant genes, 
such as the transcription factor gene TCF7 (P = 6.027 × 10
-10), have not yet been linked in a molecular biological study to 
ethanol; however, they have been found in other bioinformatics studies to be significantly associated with ethanol or with 
alcohol withdrawal
55 and therefore are encouraging targets for future biological studies of alcohol dependence.  
6.2  Obesity 
When the same procedure was conducted with the context “obesity,” the algorithm just as successfully identified diseases 
relevant to the context concept (Table 3). Obesity, unspecified is a synonym of the concept itself; morbid obesity, defined as 
weighing 45 kg or more above the ideal weight or having a BMI of at least 40, is a subset of the context
56. Polyphagia, an 
eating disorder characterized by excessive consumption of food, can cause weight gain and lead to obesity. Alcohol intake is 
another potential cause of obesity
57, and both alcohol and obesity are associated with fatty liver disease
58 (alcoholic liver 
damage, alcohol induced liver disorder). Obesity increases the risk of cholelithiasis, the development of gallstones, especially 
during the weight loss process
59 and is highly associated with polycystic ovary disease (ovarian dysfunction, ovarian non-
neoplastic disease), with around 30% of individuals with polycystic ovary disease being obese
60. There exists a genetic 
disorder, Ayazi syndrome, characterized by obesity, choroideremia, and congenital deafness
61.  
Similar to the case of the context “alcoholism,” the proposed method identified as significant a promising mix of already-
corroborated and potentially-related genes for the context “obesity.” For instance, TGFB1 (P < 10
-7), a tissue growth factor 
that regulates proliferation, migration, and differentiation of diverse cells, is linked to abdominal obesity and insulin and 
glucose  imbalance
62.  PPARD ( P <  1 0
-7)  activates  other  genes  that  direct  fatty  acid  catabolism  and  thermogenesis; 
underexpression of PPARD results in obesity
63, while PPARD agonists mimic exercise and make promising targets for 
treatment of metabolic syndromes
63-65. UBB (P < 10
-6) is one of several genes that codes for ubiquitin, a protein-recycling 
regulator involved in lipid metabolism and whose levels are inversely associated with BMI
66. Indeed, mice lacking the UBB 
gene exhibit adult-onset obesity
67. CARTPT (P < 10
-6) encodes hypothalamic satiety factors
66, the dysregulation of which may 
lead to overeating, and FADS1 (P < 10
-10), which codes for fatty acid desaturase, is related to lipid metabolism and the plasma 
triacylglycerol  response
69;  both  genes  easily  might  relate  to  obesity.  One  interesting  find  was  YWHAH  (P <  10
-9). 
Polymorphisms  of  YWHAH a r e  a s sociated  with  schizophrenia,  and  antipsychotic  drugs
70,  including  schizophrenia  me-
dications, are known to induce obesity
71. Perhaps, YWHAH is a missing link in knowledge that this method has identified.  
 
 
 
 
 
 
 
 
 
Table 3. The ten Disease Ontology (source) terms identified as most strongly linked to the context “obesity.” 
6  Discussion and Future Work 
Our technique can be seen as the first “automatic” probabilistic inference algorithm that uses large biomedical ontologies in 
conjunction with the vast corpus of existing biomedical literature and experimental data to address specific queries. Of the 
many probabilistic Bayesian frameworks proposed so far, only this one uses context-specific formulae to map concepts and to 
calculate conditional probabilities and specializes on a context-specific Bayesian network structure for inference. Therefore, 
inference using this technique is customized for the researcher’s interests than inference using previous methods. 
Disease Term 
Stu 
L  BF  p-value  
Obesity, unspecified  12225.085  630.816  5.999 × 10
-4 
Polyphagia  11458.037  20.524  3.102 × 10
-3 
Morbid obesity  5790.621  11.878  6.067 × 10
-3 
Alcoholic liver damage, unspecified  1416.854  7.704  1.047 × 10
-2 
Eating disorder, unspecified  163.686  16.905  3.929 × 10
-3 
Cholelithiasis  123.205  6.733  1.246 × 10
-2 
Choroideremia  123.205  6.733  1.246 × 10
-2 
Alcohol induced liver disorder  113.348  6.733  1.246 × 10
-2 
Ovarian dysfunction  93.180  15.432  4.392 × 10
-3 
Ovarian non-neoplastic disease  93.180  15.432  4.392 × 10
-3 
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In this particular work, the proposed framework was effectively used to identify disease concepts and genes related to a 
context pathology of interest using existing knowledge embedded in literature and in ontologies. Identified disease concepts 
were invariably closely related to the context. Many of the genes the method identified likewise were known to be associated 
with the context pathology. Of the remaining genes, many had functions that could logically link them to the context concept 
or  had  been  identified  by  other  bioinformatics  studies  as  differentially  expressed  in  individuals  exhibiting  the  context 
pathology. Such genes are promising and interesting because they may constitute new links that augment existing knowledge. 
The disease concepts and genes identified here may seem to be new information for a researcher with a specific query but no 
prior information.  
All inferences are drawn from the annotated knowledge base that the framework uses as data. Therefore, it is critical that the 
annotation methods and the selection of data and literature included are comprehensive and representative. We must assume 
that our knowledge base satisfies the previous condition. Nonetheless, this work advances our ability to generate inferences 
from such bases. Because literature, experimental data, and ontologies continually evolve, the database must be up-to-date to 
comprehensively use the prior biomedical knowledge available. We intend to fully automate the data-preparation process in 
the future and integrate it with the inference framework presented here. 
The proposed algorithm can be enhanced to improve its utility as an inferential tool. In this work, a query consists of a context 
concept of interest and two ontologies of terms from which connections are drawn. In future studies, we intend to extend the 
algorithm to be able to handle more complex queries. Additionally, future work can examine the predictive power of the 
framework in identifying drug-disease, drug-pathway, and pathway-disease relationships. 
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